TGBA01AD

From Wikipedia the free encyclopedia

TGBA01AD
Clinical data
Other namesFKB01MD
Routes of
administration		By mouth
Pharmacokinetic data
Bioavailability17%[1]
Elimination half-life4 hours[1]

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.[2][1][3] It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.[4]

See also

[edit]

References

[edit]
  1. ^ a b c "FKB01MD". Fabre-Kramer.
  2. ^ "Drugs in Clinical Development for Major Depressive Disorder". Pharmaceutical Medicine. 27 (1): 35–42. 2013. doi:10.1007/s40290-013-0007-5. ISSN 1178-2595. S2CID 16286323.
  3. ^ Żmudzka E, Sałaciak K, Sapa J, Pytka K (October 2018). "Serotonin receptors in depression and anxiety: Insights from animal studies". Life Sciences. 210: 106–124. doi:10.1016/j.lfs.2018.08.050. PMID 30144453. S2CID 52090587.
  4. ^ "TGBA01AD". AdisInsight. Springer Nature Switzerland AG.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=TGBA01AD&oldid=1254858289"